Hepatitis Monthly

Published by: Kowsar

Interleukin 28B Genetic Polymorphism and Spontaneous Recovery from Hepatitis B Virus Infection in an Iranian Azeri Population

Jafar Mehdizadeh Baghbani 1 , Sousan Mirnajd Gerami 2 , Morteza Ghojazadeh 3 , Morteza Jabbarpour Bonyadi 4 and Mohammad Hossein Somi 1 , *
Authors Information
1 MD, Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 MSc, Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 MD, Iranian Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
4 PhD, Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Article information
  • Hepatitis Monthly: September 2017, 17 (9); e11706
  • Published Online: September 19, 2017
  • Article Type: Research Article
  • Received: October 26, 2016
  • Revised: June 26, 2017
  • Accepted: September 3, 2017
  • DOI: 10.5812/hepatmon.11706

To Cite: Mehdizadeh Baghbani J, Mirnajd Gerami S, Ghojazadeh M, Jabbarpour Bonyadi M, Somi M H. et al. Interleukin 28B Genetic Polymorphism and Spontaneous Recovery from Hepatitis B Virus Infection in an Iranian Azeri Population, Hepat Mon. 2017 ; 17(9):e11706. doi: 10.5812/hepatmon.11706.

Abstract
Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401[DOI][PubMed]
  • 2. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-45[DOI][PubMed]
  • 3. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10): 1100-4[DOI][PubMed]
  • 4. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10): 1105-9[DOI][PubMed]
  • 5. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010; 52(1): 33-7[DOI][PubMed]
  • 6. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265): 798-801[DOI][PubMed]
  • 7. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010; 139(5): 1586-92[DOI][PubMed]
  • 8. Lopusna K, Rezuchova I, Betakova T, Skovranova L, Tomaskova J, Lukacikova L, et al. Interferons lambda, new cytokines with antiviral activity. Acta Virol. 2013; 57(2): 171-9[PubMed]
  • 9. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis. 2010; 202(11): 1749-53[DOI][PubMed]
  • 10. Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int. 2011; 31(8): 1118-26[DOI][PubMed]
  • 11. Lampertico P, Vigano M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology. 2013; 57(3): 890-6[DOI][PubMed]
  • 12. Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology. 2012; 142(3): 513-520 e1[DOI][PubMed]
  • 13. Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, et al. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One. 2013; 8(2)[DOI][PubMed]
  • 14. Kim SU, Song KJ, Chang HY, Shin EC, Park JY, Kim DY, et al. Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. PLoS One. 2013; 8(7)[DOI][PubMed]
  • 15. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus infection in Iran: A systematic review. Hepat Mon. 2008; 8(4): 281-94
  • 16. Etemadi J, Somi MH, Ardalan MR, Hashemi SS, Soltani GG, Shoja MM. Prevalence and risk factors of hepatitis B infection among hemodialysis patients in Tabriz: a multicenter report. Saudi J Kidney Dis Transpl. 2012; 23(3): 609-13[PubMed]
  • 17. Somi MH, Farhang S, Miri SM, Pouri AA, Mjidi G, Alavian SM. The frequency of hepatitis D virus in patients with hepatitis B in Iran: an increasing rate? Trop Doct. 2009; 39(3): 154-6[DOI][PubMed]
  • 18. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-9[DOI][PubMed]
  • 19. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012; 12(12)[DOI][PubMed]
  • 20. Seto WK, Wong DK, Kopaniszen M, Proitsi P, Sham PC, Hung IF, et al. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis. 2013; 56(12): 1695-703[DOI][PubMed]
  • 21. Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, et al. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha. J Gastroenterol Hepatol. 2013; 28(5): 861-6[DOI][PubMed]
  • 22. Wu H, Zhao G, Qian F, Liu K, Xie J, Zhou H, et al. Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B. Liver Int. 2015; 35(2): 473-81[DOI][PubMed]
  • 23. Abdo AA, Al-Ahdal MN, Khalid SS, Helmy A, Sanai FM, Alswat K, et al. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol Int. 2013; 7(2): 533-8[DOI][PubMed]
  • 24. Karatayli SC, Bozdayi M, Karatayli E, Ozturk T, Husseini AA, Albayrak R, et al. Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B. Liver Int. 2015; 35(3): 846-53[DOI][PubMed]
  • 25. Taheri S, Aygen B, Korkmaz K, Yildiz O, Zararsiz G, Canatan H. Characterization of the Interleukin-28B Gene rs12979860 C/T Polymorphism in Turkish Chronic Hepatitis C Patients and Healthy Individuals. Balkan Med J. 2015; 32(2): 147-55[DOI][PubMed]
  • 26. Moini M, Azarpira N, Darai M, Sabet S, Geramizadeh B. Allele and Genotype Frequency of IL28B (rs12979860) in South Iranian population. Middle East J Dig Dis. 2015; 7(4): 261-2[PubMed]
  • 27. Ren S, Lu J, Du X, Huang Y, Ma L, Huo H, et al. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother. 2012; 61(9): 1433-9[DOI][PubMed]
  • 28. Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 2007; 126(1-2): 245-9[DOI][PubMed]
  • 29. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010; 139(2): 499-509[DOI][PubMed]
  • 30. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010; 52(6): 1888-96[DOI][PubMed]
  • 31. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006; 80(9): 4501-9[DOI][PubMed]
  • 32. Takahashi T. Interleukin 28B genetic polymorphism and hepatitis B virus infection. World J Gastroenterol. 2014; 20(34): 12026-30[DOI][PubMed]
  • 33. Sticchi L, Di Biagio A, Rappazzo E, Setti M, De Rosa G, De Hoffer L, et al. Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. J Prev Med Hyg. 2013; 54(2): 83-6[PubMed]
  • 34. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005; 79(15): 9369-80[DOI][PubMed]
  • 35. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood. 2009; 113(23): 5868-77[DOI][PubMed]
  • 36. Shokouhi S, Rakhshan M, Gachkar L, Khalaj E, Sazgar S. Effects of hepatitis B surface and hepatitis B core antigens from hepatitis B virus genotypes B and C on in vitro apoptosis. Hepat Mon. 2007; 4: 217-21
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments